Kučan Brlić, P., Lenac Roviš, T., Cinamon, G., Tsukerman, P., Mandelboim, O. & Jonjić, S. (2018). Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology, 16. (1), 40-52. doi: 10.1038/s41423-018-0168-y
Kučan Brlić, Paola, et al. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology, vol. 16, no. 1, 2018, pp. 40-52. https://doi.org/10.1038/s41423-018-0168-y
Kučan Brlić, Paola, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim and Stipan Jonjić. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology 16, no. 1 (2018): 40-52. https://doi.org/10.1038/s41423-018-0168-y
Kučan Brlić, P., et al. (2018) 'Targeting PVR (CD155) and its receptors in anti-tumor therapy', Cellular and Molecular Immunology, 16(1), pp. 40-52. doi: 10.1038/s41423-018-0168-y
Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology [Internet]. 2018 October 01 [cited 2024 October 03];16(1):40-52. doi: 10.1038/s41423-018-0168-y
P. Kučan Brlić, T. Lenac Roviš, G. Cinamon, P. Tsukerman, O. Mandelboim and S. Jonjić, "Targeting PVR (CD155) and its receptors in anti-tumor therapy", Cellular and Molecular Immunology, vol. 16, no. 1, pp. 40-52, October 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:504690. [Accessed: 03 October 2024]